➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,351,834

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,351,834 protect, and when does it expire?

Patent 7,351,834 protects STIVARGA and is included in one NDA.

This patent has one hundred and thirteen patent family members in fifty-one countries.

Summary for Patent: 7,351,834

Title:	.omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract:	This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s):	Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy (Hyogo, JP), Scott; William (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (Hamden, CT), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert (North Haven, CT)
Assignee:	Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:	09/889,227
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,351,834
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,351,834

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	STIVARGA	regorafenib	TABLET;ORAL	203085-001	Sep 27, 2012		RX	Yes	Yes	⤷ Try it Free	⤷ Try it Free		Y			⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 7,351,834

PCT Information
PCT Filed	January 12, 2000	PCT Application Number:	PCT/US00/00648
PCT Publication Date:	July 20, 2000	PCT Publication Number:	WO00/42012

International Family Members for US Patent 7,351,834

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	035310	⤷ Try it Free
Argentina	077485	⤷ Try it Free
Austria	321027	⤷ Try it Free
Austria	460398	⤷ Try it Free
Austria	520663	⤷ Try it Free
Austria	538794	⤷ Try it Free
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys

Mallinckrodt

Dow

McKesson

Colorcon

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.